ChinaDaily Briefs

Daily Brief China: Alibaba Group Holding , China Tower , Swire Pacific (A), Huaneng Lancang River Hydropow, Wharf Real Estate Investment C, JD Logistics , China Resources Beer Holdings, Medtide, Delhi International Airport Limited and more

In today’s briefing:

  • China Consumption Weekly (19Aug2024): China Literature, BEKE, Alibaba, JD, JD Health, Tencent Music
  • FXI Rebalance Preview: China Tower (788 HK) Could Replace CICC (3908 HK)
  • HK CEO & Director Dealings (19th Aug 2024): Merlin Selling Swire Pac/Props; Chans Buying Hang Lung
  • China A50 ETFs Rebalance Preview: Two High Probability Changes in Sep
  • Wharf REIC: Beta Play W Multiple Catalysts, Lower Rates, Weaker Currency and Returning of Shoppers
  • JD Logistics (2618 HK): There Are More Rooms
  • China Resources Beer Holdings – Interim Results Show Progress but Macro Headwinds Remain
  • Pre-IPO Medtide – The Industry, the Business and the Concerns
  • Morning Views Asia: Continuum Green Energy, Melco Resorts and Entertainment (Philippines)


China Consumption Weekly (19Aug2024): China Literature, BEKE, Alibaba, JD, JD Health, Tencent Music

By Ming Lu

  • China Literature’s revenue increased by 28% YoY in 1H24, because four novel copyrights for movies brought box office hits.
  • KE revenue increased by 20% YoY in 2Q24 compared with a 19% YoY decrease in 1Q24, as government policies supported existing home transaction.
  • Alibaba announced that it will recruit 1,000 fresh graduates for tech positions in 2025.

FXI Rebalance Preview: China Tower (788 HK) Could Replace CICC (3908 HK)

By Brian Freitas


HK CEO & Director Dealings (19th Aug 2024): Merlin Selling Swire Pac/Props; Chans Buying Hang Lung

By David Blennerhassett



Wharf REIC: Beta Play W Multiple Catalysts, Lower Rates, Weaker Currency and Returning of Shoppers

By Jacob Cheng

  • Wharf REIC reported 2% yoy core earnings growth, the first earnings increase since 2019. The results also show Hong Kong retail business is more resilient than expected
  • The upcoming catalysts include 1) lower interest rates, 2) weakening currency environment and 3) bottoming out of HK retail market
  • Market is forward-looking and we think the worst is behind us.  Valuation is very compelling.  The stock is a beta play.  BUY

JD Logistics (2618 HK): There Are More Rooms

By Osbert Tang, CFA

  • Even after the 28% surge in share price since the 1H24 result, JD Logistics (2618 HK) still deserves a look as fundamentals have improved, especially with better cost control.
  • JDL is riding on scale economies with higher asset utilisation. Quarterly margins have sustained an uptrend, reaching the highest levels since 1Q21 and it will continue.
  • We like its lower reliance on JD.com (9618 HK) and net cash of HK$2.83/share (28% of the share price). There is a massive upside in consensus forecasts too.

China Resources Beer Holdings – Interim Results Show Progress but Macro Headwinds Remain

By Rikki Malik

  • The company’s strategy of premiumisation continues to be executed to plan
  • Despite the derating, investors will wait until seeing concrete signs of a turn in the Chinese consumer
  • Continues to be a liquid proxy for Chinese consumption with no technology regulation risk

Pre-IPO Medtide – The Industry, the Business and the Concerns

By Xinyao (Criss) Wang

  • Medtide relies heavily on limited number of customers to contribute performance. If there is any significant reduction in demand by its major customers, Medtide’s performance growth would be materially/adversely affected.
  • Due to geopolitical conflicts, pharmaceutical companies are becoming more cautious about their reliance on China CXO. So, the development of Medtide’s overseas business would become more uncertain in this context.
  • Medtide’s business scale is still small and its position in the global peptide CXO industry is not as strong as described. Valuation of Medtide should be lower than peers.

Morning Views Asia: Continuum Green Energy, Melco Resorts and Entertainment (Philippines)

By Leonard Law, CFA

Lucror Analytics Morning Views comprise our fundamental credit analysis, opinions and trade recommendations on high yield issuers in the region, based on key company-specific developments in the past 24 hours. Our Morning Views include a section with a brief market commentary, key market indicators and a macroeconomic and corporate event calendar.


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars